NCT00117143View on ClinicalTrials.gov

Amgen Megakaryopoiesis Protein 2 (AMG 531) in Thrombocytopenic Subjects With Immune Thrombocytopenic Purpura (ITP)

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 2, 2002

Primary Completion Date

July 19, 2004

Study Completion Date

July 19, 2004

Conditions

Thrombocytopenic Purpura

Interventions

DRUG

Romiplostim

Administered subcutaneously on day 1 and on day 15 or 22 if the platelet count was ≤ 50 x 10⁹/L and not rising, peak platelet count was ≤ 450 x 10⁹/L and no serious adverse events related to treatment were observed.